Global In-situ Hybridization Market Analysis
Overview
In-situ hybridization is an analytical method for determining the location of particular DNA/RNA elements in chromosomes. The capacity of the DNA helix to re-form or re-nature when given suitable conditions provides the basis for molecular hybridization. A tagged DNA or RNA sequence is used as a probe in chemical hybridization to recognize or measure the naturally occurring DNA or RNA sequence in a biological sample. A nucleic acid probe is made, tagged, purified, and annealed to a specific target. It is a crucial approach in genetic research and the discovery of gene-based therapy, particularly in personalized medicine.
In-situ hybridization is divided into two categories: fluorescence in-situ hybridization (FISH), which uses a fluorescence probe, and chromogenic in-situ hybridization, which uses a chromogenic probe (CISH). FISH allows numerous targets to be seen in the same sample and is generally used to identify the existence of a certain gene, the number of copies of that gene in the specimen, and alteration research. CISH allows for the acquisition of hereditary data in the context of cell shape and is most commonly used in molecular pathology diagnoses.
Get FREE Sample PDF Including COVID-19 Impact Analysis
Drivers
In situ hybridization, particularly FISH, is primarily used for the clinical diagnosis of chronic illnesses such as cancer, immunological diseases, and some uncommon diseases caused by chromosomal abnormalities. As a result, growing cancer incidence is projected to be one of the key reasons pushing the global in-situ hybridization market forward. With the aid of specific assay kits available from important companies, the FISH method is utilized to discover mutated genes in patients.
As per a factsheet published by the World Health Organization (WHO), cancer is one of the main causes of illness and mortality globally, with approximately 14 million new cases and 8.8 million deaths in 2012.
In addition, increased efforts in the fields of genetic research, genetic diagnostics, and gene-based therapy will drive the in-situ hybridization market forward. Companies are increasingly focusing on customized therapy, such as CAR-T cell treatments, to discover a cure for cancer. Gene-based identification, which is gaining momentum in the marketplace, can be used to track future illness risk. PerkinElmer, Inc., and Helix established a partnership in April 2018 to develop and market exome sequencing-based diagnostic tests that can pinpoint particular genes in a sample.
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2057
Regional Analysis
During the forecast period, North America is projected to maintain its dominance in the global in-situ hybridization market. The U.S. has a high incidence of many cancers. According to a factsheet released by the American Cancer Society in 2018, cancer is the second largest cause of death after cardiovascular disease. Around 1.7 million new cancer cases are expected to be diagnosed, with over half a million deaths. Furthermore, the presence of significant companies in the U.S. that supply sophisticated assay kits and probes for diagnostic and research and development operations will support the global in-situ hybridization market growth in this area.
Competitive Landscape
Major companies contributing in the global in-situ hybridization market are PerkinElmer, Inc., Merck KGaA, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Abbott Laboratories, Inc., Bio SB Inc., Advanced Cell Diagnostics, Inc., BioGenex Laboratories, Inc., Exiqon A/S, Leica Biosystems Nussloch GmbH, and Oxford Gene Technology.
Request PDF Research Report Brochure
Key Developments
Agilent Technologies Inc. released new FISH and CISH probes for in-situ hybridization in June 2018. The novel probes solve the requirement to analyze data from fluorescence in-situ hybridization (FISH) and chromogenic in-situ hybridization (CISH) in a clear and appropriate way.
Oxford Gene Technology, an organismal biology firm, released two novel CE-IVD tagged fluorescence in-situ hybridization (FISH) probes in 2016, extending the diagnostic options for lung cancer. The Cytocell Aquarius ROS1 Plus Breakapart and RET Breakapart probes identify genomic alterations relating to non-cell lung cancer in a precise and accurate manner.
Main points in In-situ Hybridization Market Report Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global In-situ Hybridization Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: In-situ Hybridization Industry Impact
Chapter 2 Global In-situ Hybridization Competition by Types, Applications, and Top Regions and Countries
2.1 Global In-situ Hybridization (Volume and Value) by Type
2.3 Global In-situ Hybridization (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global In-situ Hybridization Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America In-situ Hybridization Market Analysis
Chapter 6 East Asia In-situ Hybridization Market Analysis
Chapter 7 Europe In-situ Hybridization Market Analysis
Chapter 8 South Asia In-situ Hybridization Market Analysis
Chapter 9 Southeast Asia In-situ Hybridization Market Analysis
Chapter 10 Middle East In-situ Hybridization Market Analysis
Chapter 11 Africa In-situ Hybridization Market Analysis
Chapter 12 Oceania In-situ Hybridization Market Analysis
Chapter 13 South America In-situ Hybridization Market Analysis
Chapter 14 Company Profiles and Key Figures in In-situ Hybridization Business
Chapter 15 Global In-situ Hybridization Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837